United States: The Proposed Medicare OPPS Payment Rule: CMS Gets Tough On Site Neutral Payment

Last Updated: August 10 2018
Article by Susan Feigin Harris and Kathleen P. Rubinstein

Topping the list of significant policy changes are efforts by the Centers for Medicare & Medicaid Services (CMS) to expand site neutral reductions in payment for outpatient clinic visits and to reduce payment for 340B drugs furnished by certain off-campus provider-based departments.

CMS has released its annual proposed policy and payment update under the Hospital Outpatient Prospective Payment System (OPPS). Consistent with the steady stream of payment rules released by CMS over the past 90 days, this latest proposed rule reflects many of the agency's priorities including lowering drug costs, reducing beneficiary out-of-pocket costs, addressing the opioid crisis, and lessening the regulatory burden on healthcare providers. And in keeping with the other proposed payment regulations, requests for information on a host of issues including interoperability and price transparency concerns also figure prominently. Most notable, however, are the proposed policy changes aimed at reducing the payment differential between sites of service in the proposed rule.

Comments are due by Sept. 24, 2018.

Site Neutral Payment Policy Changes

Payment for Hospital Outpatient Clinic Visits

To the extent that similar services can be safely provided in more than one setting, it is not prudent for the Medicare program to pay more for these services in one setting than another.

As an effective means for controlling "unnecessary volume increases," CMS proposes to eliminate the payment differential for hospital outpatient clinic visits furnished in off-campus provider based departments (PBDs) excepted under Section 603 of the Balanced Budget Act of 2015 and non-excepted off-campus PBDs. To that end, clinic visit services using HCPCS code G0463 would be paid at the physician fee schedule rate for all off-campus PBDs effective January 1, 2019, lowering copayments for beneficiaries.

The agency is also soliciting comments on expanding this policy to additional items and services "that may represent unnecessary increases in hospital outpatient department utilization."

Payment for Excepted Items and Services

... we continue to be concerned that if excepted off-campus PBDs are allowed to furnish new types of services that were not provided at the excepted off-campus PBDs prior to the date of enactment of the Bipartisan Budget Act of 2015 and can be paid OPPS rates for these new types of services, hospitals may be able to purchase additional physician practices and add those physicians to existing excepted off-campus PBDs.

CMS seeks to limit service line expansion for excepted off-campus PBDs using 19 clinical families identified in Table 32 of the proposed rule. As a result, services furnished by an excepted off-campus PBD from any clinical family of services (Table 32) from which it did not furnish an item or service and subsequently bill for during a baseline period of Nov. 1, 2014, through Nov. 1, 2015, would be paid the reduced physician fee schedule amount. If an excepted off-campus PBD furnishes a new item or service from a clinical family of services listed in Table 32 from which the off-campus PBD furnished a service from November 1, 2014, through November 1, 2015, the service would continue to be paid under the OPPS. For providers that met the "mid-build" requirement, CMS proposes establishing a one-year baseline period that begins on the first date the off-campus PBDs furnished a service billed under the OPPS.

Payment for 340B Drugs

We agree with commenters that the difference in the payment amounts for 340B acquired drugs furnished by hospital outpatient departments--excepted off-campus PBDs versus nonexcepted off-campus PBDs--creates an incentive for hospitals to move drug administration services for 340B-acquired drugs to nonexcepted off-campus PBDs to receive a higher payment amount for these drugs, thereby undermining our goals of reducing beneficiary cost-sharing for these drugs and biologicals ....

The proposed rule would pay 340B-acquired drugs furnished by nonexcepted, off-campus PBDs under a formula determined by the average sales price (ASP) minus 22.5% for CY 2019. OPPS-exempt cancer hospitals, children's hospitals, and rural sole community hospitals would be exempt from this policy change.

Off-campus Provider-Based Emergency Departments

We agree with MedPAC's recommendation and believe we need to develop data to assess the extent to which OPPS services are shifting to off-campus provider-based emergency departments. Therefore, we are announcing in this proposed rule that we are implementing through the subregulatory HCPCS modifier process a new modifier for this purpose effective beginning January 1, 2019.

CMS proposes creating a HCPCS modifier (ER—Items and services furnished by a provider-based off-campus emergency department) that would be reported with every claim line for outpatient hospital services furnished in an off-campus provider-based emergency department. Critical access hospitals would not be required to report this modifier under the proposed rule.

Operating Payment Update

For hospitals that successfully meet the hospital outpatient quality reporting (OQR) requirements, CMS proposes to increase payment rates by 1.25% for CY 2019. This update is based on a proposed hospital market basket increase of 2.8% minus a productivity adjustment of 0.8 percentage points and a statutory reduction of 0.75 percentage points. However, when compared to FY 2018, overall payment for hospital outpatient departments will result in a net decrease of 1.2% when the proposed site neutral policy changes are factored in because they would not be budget neutral.

Hospital Outpatient Quality Reporting Program

CMS has identified 10 measures as being "topped out" and appropriate for removal from the OQR beginning with the CY 2020 and CY 2021 payment determination periods. The proposal to remove these measures is consistent with the agency's Meaningful Measures Initiative, which also heavily influenced CMS's proposed rule for inpatient hospital payment earlier in the Spring. A Fact Sheet published by CMS details the eliminated measures and the rationale behind their removal.

Removing Pain Management Questions from the Patient Experience Survey

Responding to stakeholder concerns that hospital staff may feel pressured to prescribe opioids, CMS proposes to remove the "Communication About Pain" questions from the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey effective with January 2022 discharges for the FY 2024 payment determination.

In its final report, the President's Commission on Combating Drug Addiction and the Opioid Crisis recommended removal of the HCAHPS pain management questions under the Hospital Inpatient Quality Reporting (IQR) Program to ensure providers are not incentivized to offer opioids in order to raise their HCAHPS Survey score.

Drug Payment Policy

Nonpass-through biosimilars acquired under the 340B program would be paid at ASP minus 22.5% of the biosimilar's own ASP rather than ASP minus 22.5% of the reference product's ASP.

CMS proposes to pay separately payable drugs and biological products that do not have pass-through payment status and are not acquired under the 340B Program at wholesale acquisition cost (WAC) plus 3% instead of WAC plus 6% if ASP data are not available.

If WAC data are not available for a drug or biological product, CMS proposes to pay separately payable drugs and biological products at 95% of the average wholesale price (AWP) consistent with current policy.

Drugs and biologicals acquired under the 340B Program would continue to be paid at ASP minus 22.5%, WAC minus 22.5%, or 69.46% of AWP, as applicable.

CMS is seeking feedback through a Request for Information on leveraging the agency's authority under the competitive acquisition program (CAP) to test whether allowing private sector vendors to administer payment arrangements for separately payable Part B drugs and biologicals "would improve beneficiary access and quality of care while reducing Medicare expenditures." It is anticipated that the proposal, which is intended to build on the President's Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, would create incentives for lower list prices and lower out-of-pocket costs and accelerate the move to a value-based healthcare system, according to CMS.

New Technology APC Payment

In an effort to promote payment rate "predictability" for low-volume new technology procedures, CMS proposes to apply a "smoothing methodology" based on multiple years of claim data. To that end, the agency would use up to four years of data to calculate the geometric mean, the median, and the arithmetic mean costs for services assigned to new technology ambulatory payment classifications (APCs) with fewer than 100 claims per year under the OPPS.

Comprehensive Ambulatory Payment Classifications

For CY 2019, the proposed rule would create three new comprehensive APCs (C-APCs) for ears, nose, and throat (ENT) and vascular procedures – bringing the total number of C-APCs to 65.

Inpatient Only List

The following procedures would be removed from the inpatient only (IPO) list for CY 2019:

  • CPT code 31241 - Nasal/sinus endoscopy, surgical; with ligation of sphenopalatine artery
  • CPT code 01402 - Anesthesia for open or surgical arthroscopic procedures on knee joint; total knee arthroplasty

CMS would also add one procedure to the IPO list described by HCPCS code C9606 (Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel).

Promoting Interoperability

CMS includes a Request for Information on solutions for achieving interoperability in the proposed rule. Specifically, the agency seeks feedback on revising the Conditions of Participation to promote electronic data sharing.

Price Transparency

Consistent with the proposed physician fee schedule rule for CY 2019, CMS invites comments via a Request for Information on potential actions appropriate for helping patients understand their potential financial liability for medical services and to compare charges for similar services across providers and suppliers and in different medical settings.

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions